

# Robert I Haddad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857282/publications.pdf>

Version: 2024-02-01

247  
papers

25,188  
citations

9786

73  
h-index

7518

151  
g-index

251  
all docs

251  
docs citations

251  
times ranked

22178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). <i>Cancer</i> , 2022, 128, 487-496.	4.1	12
2	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	7.0	45
3	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
4	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
5	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
6	NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 224-234.	4.9	169
7	Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. <i>Head and Neck</i> , 2022, , .	2.0	3
8	Use of Fluoro- <sup>18</sup> F-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 268.	2.2	3
9	Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. <i>Head and Neck</i> , 2022, 44, 722-734.	2.0	6
10	Head and neck cancer: high-end technology is no guarantee of high-quality care “ Authors' reply. <i>Lancet, The</i> , 2022, 399, 2102.	13.7	1
11	Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2622-2622.	1.6	0
12	Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. <i>Cell</i> , 2022, 185, 2918-2935.e29.	28.9	113
13	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
14	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. <i>Oral Oncology</i> , 2021, 112, 105087.	1.5	8
15	Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab”Reply. <i>JAMA Oncology</i> , 2021, 7, 309.	7.1	1
16	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	1.6	178
17	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 450-462.	10.7	287
18	Reply to “Keynote 48: Is it really for everyone?” <i>Oral Oncology</i> , 2021, 115, 105108.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2021, 39, 6008-6008.	1.6	19
20	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. Journal of Clinical Oncology, 2021, 39, 10536-10536.	1.6	0
21	Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology, 2021, 39, 6053-6053.	1.6	7
22	The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with <i>HRAS</i> mutations.. Journal of Clinical Oncology, 2021, 39, TPS6087-TPS6087.	1.6	3
23	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	7.0	51
24	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. Journal of Clinical Oncology, 2021, 39, 1856-1864.	1.6	100
25	A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncology, 2021, 119, 105366.	1.5	31
26	Head and neck cancer. Lancet, The, 2021, 398, 2289-2299.	13.7	280
27	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer, 2021, 160, 78-83.	2.0	10
28	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Research Communications, 2021, 1, 30-40.	1.7	10
29	Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Diseases, 2020, 26, 325-333.	3.0	33
30	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	7.0	163
31	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell, 2020, 38, 769-770.	16.8	54
32	Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head and Neck, 2020, 42, 3670-3677.	2.0	3
33	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. JAMA Oncology, 2020, 6, 1563.	7.1	198
34	Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investigative Otolaryngology, 2020, 5, 1063-1069.	1.5	7
35	Keynote 48: Is it really for everyone?. Oral Oncology, 2020, 105, 104762.	1.5	8
36	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. Journal of Clinical Oncology, 2020, 38, 2773-2781.	1.6	33

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	2.1	16
38	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020, 31, 942-950.	1.2	240
39	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 105, 104676.	1.5	16
40	The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2020, 25, 598-608.	3.7	26
41	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz094.	2.9	114
42	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	3.4	47
43	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. <i>Oral Oncology</i> , 2020, 106, 104690.	1.5	21
44	Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6511-6511.	1.6	24
45	A phase II study of nivolumab (N) plus ipilimumab (I) in radioiodine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6513-6513.	1.6	34
46	Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 873-898.	4.9	633
47	The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6593-TPS6593.	1.6	1
48	Targeted therapy: Precision comes to life. , 2020, , 39-51.		0
49	Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 982-984.	4.9	0
50	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1660-1667.	2.5	127
51	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 132-139.	0.8	8
52	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
53	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
54	Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2019, 95, 120-126.	1.5	33

#	ARTICLE	IF	CITATIONS
55	Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 689-700.	1.5	32
56	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019, 123, 138-145.	2.8	13
57	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019, 97, 82-91.	1.5	3
58	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 815.	2.8	53
59	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2019, 5, 1170.	7.1	34
60	Everolimus in Anaplastic Thyroid Cancer: A Case Series. <i>Frontiers in Oncology</i> , 2019, 9, 106.	2.8	25
61	Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2019, 113, 1-9.	2.8	19
62	Weekly paclitaxel, carboplatin, cetuximab, and docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 471-477.	1.2	17
63	IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. <i>Head and Neck</i> , 2019, 41, 959-966.	2.0	8
64	EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6012-6012.	1.6	34
65	A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6082-6082.	1.6	6
66	KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6090-TPS6090.	1.6	19
67	Impact of dental insurance coverage on presentation, long-term outcomes, and symptom burden in locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18230-e18230.	1.6	0
68	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	3.7	30
69	Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. <i>Oral Oncology</i> , 2018, 81, 1-9.	1.5	8
70	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
71	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. <i>Annals of Oncology</i> , 2018, 29, 1130-1140.	1.2	94
72	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. <i>Clinical Cancer Research</i> , 2018, 24, 1546-1553.	7.0	86

#	ARTICLE	IF	CITATIONS
73	Management of treatment-related toxicities in advanced medullary thyroid cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 64-73.	7.7	38
74	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	190
75	NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1429-1440.	4.9	249
76	Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1269-1270.	4.9	0
77	NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 479-490.	4.9	439
78	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.8	24
79	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
80	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2018, 4, 1583.	7.1	84
81	Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. <i>Annals of Oncology</i> , 2018, 29, 1980-1986.	1.2	94
82	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	21.4	438
83	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
84	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	1.5	15
85	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 82, 83-90.	1.5	19
86	Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	21
87	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. <i>Oral Oncology</i> , 2017, 67, 77-82.	1.5	28
88	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 67, 61-69.	1.5	42
89	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	3.7	57
90	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. <i>Endocrine</i> , 2017, 56, 121-128.	2.3	82

#	ARTICLE	IF	CITATIONS
91	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2017, 19, 129-136.	1.7	22
92	Management of elderly patients with locoregionally confined head and neck cancer. <i>Lancet Oncology</i> , The, 2017, 18, e274-e283.	10.7	51
93	NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 761-770.	4.9	263
94	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 73, 160-165.	1.5	7
95	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2017, 28, 2526-2532.	1.2	70
96	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
97	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 191.	2.8	42
98	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	1.6	527
99	Title is missing!., 2017, , .		4
100	Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6009-6009.	1.6	41
101	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	1.6	20
102	JAVELIN head and neck 100: A phase 3 trial of avelumab in combination with chemoradiotherapy (CRT) vs CRT for 1st-line treatment of locally advanced squamous cell carcinoma of the head and neck (LA) Tj ETQq0 0 0 rgBIL4Overload 10 Tf 50		
103	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	1.6	1
104	Advances in Collaborative Practice for Patients With Head and Neck Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 261-265.	0.4	0
105	Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. <i>Journal of Oncology Practice</i> , 2016, 12, e77-e82.	2.5	9
106	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
107	Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. <i>European Journal of Cancer Prevention</i> , 2016, 25, 344-348.	1.3	30
108	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. <i>Head and Neck</i> , 2016, 38, E1618-24.	2.0	7



#	ARTICLE	IF	CITATIONS
109	Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1530-1538.	2.0	9
110	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	6.4	66
111	Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. <i>Oncologist</i> , 2016, 21, 1522-1529.	3.7	18
112	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
113	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
114	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. <i>Oral Oncology</i> , 2016, 61, 19-26.	1.5	20
115	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	4.1	145
116	Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo. <i>Cancer</i> , 2016, 122, 3592-3595.	4.1	3
117	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	3.4	81
118	The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. <i>Annals of Oncology</i> , 2016, 27, 1619-1625.	1.2	101
119	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. <i>Annals of Oncology</i> , 2016, 27, 1585-1593.	1.2	41
120	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	7.0	51
121	Multidisciplinary Approach of Unresectable Head and Neck Cancer. , 2016, , 617-624.		1
122	Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6011-6011.	1.6	11
123	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6012-6012.	1.6	33
124	Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6029-6029.	1.6	1
125	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6052-6052.	1.6	1
126	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9577-9577.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Anaplastic Thyroid Carcinoma, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1140-1150.	4.9	92
128	Head and Neck Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 847-856.	4.9	185
129	Ensuring Head and Neck Oncology Patients Receive Recommended Pretreatment Dental Evaluations. Journal of Oncology Practice, 2015, 11, 151-154.	2.5	8
130	Sequential and Concurrent Chemoradiation. Hematology/Oncology Clinics of North America, 2015, 29, 1061-1074.	2.2	2
131	Barriers to clinical trial recruitment in head and neck cancer. Oral Oncology, 2015, 51, 203-211.	1.5	27
132	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 1447-1456.	7.0	235
133	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncology, 2015, 51, 751-758.	1.5	34
134	Marital status and head and neck cancer outcomes. Cancer, 2015, 121, 1273-1278.	4.1	136
135	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 583-594.	10.7	358
136	Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncology, 2015, 1, 907.	7.1	82
137	Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M) Tj ETQq1 1 0.784314 rgBT /Overlock (LUX-H&N1).. Journal of Clinical Oncology, 2015, 33, 6023-6023.	1.6	7
138	Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options. Current Treatment Options in Oncology, 2014, 15, 595-610.	3.0	16
139	Human papillomavirus-“associated adenocarcinoma of the palatine tonsil” reply. Human Pathology, 2014, 45, 895.	2.0	0
140	Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15544-15549.	7.1	317
141	Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. Journal of Clinical Oncology, 2014, 32, 2408-2415.	1.6	139
142	Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 2014, 371, 1426-1433.	27.0	290
143	Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer, 2014, 14, 473.	2.6	20
144	Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. Cancer Treatment Reviews, 2014, 40, 390-404.	7.7	77

#	ARTICLE	IF	CITATIONS
145	Thyroid Carcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1671-1680.	4.9	147
146	Head and Neck Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1454-1487.	4.9	192
147	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 257-264.	10.7	617
148	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research, 2013, 73, 5195-5205.	0.9	153
149	A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncology, 2013, 49, 835-841.	1.5	54
150	Human papillomavirus-associated adenocarcinoma of the base of the tongue. Human Pathology, 2013, 44, 1516-1523.	2.0	19
151	Larynx Preservation: A Debate Worth Preserving. Journal of Clinical Oncology, 2013, 31, 3170-3170.	1.6	10
152	Induction Chemotherapy for Locoregionally Advanced Head and Neck Cancer: Past, Present, Future?. Oncologist, 2013, 18, 288-293.	3.7	27
153	Organ Preservation for Adenoid Cystic Carcinoma of the Larynx. Oncologist, 2013, 18, 579-583.	3.7	17
154	Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope, 2013, 123, 3066-3073.	2.0	27
155	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer, 2013, 119, 4268-4276.	4.1	107
156	Vandetanib for the Treatment of Medullary Thyroid Cancer. Clinical Cancer Research, 2013, 19, 524-529.	7.0	71
157	How to Incorporate New Tyrosine Kinase Inhibitors in the Treatment of Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology, 2013, 31, 3618-3620.	1.6	12
158	Trastuzumab for the Treatment of Salivary Duct Carcinoma. Oncologist, 2013, 18, 294-300.	3.7	155
159	New Developments in Thyroid Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 705-707.	4.9	10
160	Head and Neck Cancers, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 917-923.	4.9	141
161	Locally Advanced Head and Neck Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 237-244.	3.8	2
162	Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).. Journal of Clinical Oncology, 2013, 31, 6030-6030.	1.6	6

#	ARTICLE	IF	CITATIONS
163	Locally Advanced Head and Neck Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 237-244.	3.8	9
164	Biomarkers of HPV in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2012, 72, 5004-5013.	0.9	122
165	Metastatic Human Papillomavirus-Positive Nasopharyngeal Carcinoma With an Unusual Pattern of Aggressive Hematogenous Spread. Journal of Clinical Oncology, 2012, 30, e321-e323.	1.6	10
166	Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Annals of Oncology, 2012, 23, 2391-2398.	1.2	19
167	Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 320-338.	4.9	29
168	Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 308-314.	0.8	104
169	Acupuncture for dysphagia after chemoradiation in head and neck cancer: Rationale and design of a randomized, sham-controlled trial. Contemporary Clinical Trials, 2012, 33, 700-711.	1.8	21
170	Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy. Community Oncology, 2012, 9, 188-197.	0.2	2
171	Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology, 2012, 48, 1281-1288.	1.5	71
172	Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature. Oral Oncology, 2012, 48, 1085-1089.	1.5	75
173	Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer, 2012, 76, 144-149.	2.0	44
174	Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer. Cancer, 2012, 118, 1811-1817.	4.1	28
175	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. Journal of Clinical Oncology, 2012, 30, 5501-5501.	1.6	30
176	Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 153-159.	10.7	371
177	Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX 324. International Journal of Radiation Oncology Biology Physics, 2011, 81, e813-e818.	0.8	45
178	Treatment of Oral Cavity Squamous Cell Carcinoma With Adjuvant or Definitive Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e215-e222.	0.8	61
179	Head and Neck Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 596-650.	4.9	213
180	Patient-reported receipt of and interest in smoking cessation interventions after a diagnosis of cancer. Cancer, 2011, 117, 2961-2969.	4.1	53

#	ARTICLE	IF	CITATIONS
181	Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1405-1411.	0.8	50
182	Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. <i>Bone Marrow Transplantation</i> , 2011, 46, 884-891.	2.4	96
183	Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. <i>Annals of Oncology</i> , 2011, 22, 1071-1077.	1.2	413
184	Swallowing Function following Postchemoradiotherapy Neck Dissection. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 428-434.	1.9	21
185	Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. <i>British Journal of Cancer</i> , 2011, 104, 1896-1905.	6.4	63
186	Multidisciplinary Approach of Unresectable Head and Neck Cancer. , 2011, , 333-337.		0
187	Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1228-1274.	4.9	194
188	Medullary Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 512-530.	4.9	70
189	Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 367-374.	1.9	16
190	Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. <i>Cancer</i> , 2010, 116, 4761-4768.	4.1	70
191	Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. <i>Laryngoscope</i> , 2010, 120, 261-266.	2.0	35
192	Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 342-347.	1.2	52
193	Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer: A Case Series Report. <i>Integrative Cancer Therapies</i> , 2010, 9, 284-290.	2.0	28
194	Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2664-2671.	3.6	233
195	Polymerase Chain Reaction Detection of HPV in Squamous Carcinoma of the Oropharynx. <i>American Journal of Clinical Pathology</i> , 2010, 134, 36-41.	0.7	43
196	Re: Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1157-1158.	6.3	3
197	Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 4448-4453.	1.6	54
198	Induction Chemotherapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e52-e53.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. <i>Annals of Oncology</i> , 2009, 20, 921-927.	1.2	134
200	Seeking alternative biological therapies: The future of targeted molecular treatment. <i>Oral Oncology</i> , 2009, 45, 447-453.	1.5	14
201	Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. <i>Cancer</i> , 2009, 115, 4514-4523.	4.1	85
202	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 725-733.	0.8	80
203	̂ <sup>2</sup> -Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6222-6228.	1.6	55
204	Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. <i>Cancer Prevention Research</i> , 2009, 2, 776-781.	1.5	260
205	Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1110-1118.	0.8	211
206	HPV16 transmission between a couple with HPV-related head and neck cancer. <i>Oral Oncology</i> , 2008, 44, 812-815.	1.5	37
207	Multidisciplinary Approach to Cancer Treatment: Focus on Head and Neck Cancer. <i>Dental Clinics of North America</i> , 2008, 52, 1-17.	1.8	27
208	Induction Chemotherapy in Locally Advanced Head and Neck Cancer: A New Standard of Care?. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1155-1163.	2.2	24
209	Recent Advances in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 1143-1154.	27.0	825
210	Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer. <i>Oncologist</i> , 2008, 13, 886-898.	3.7	174
211	A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2008, 1, 339-348.	1.5	24
212	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 317-323.	4.5	185
213	Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1705-1715.	27.0	1,537
214	Retropharyngeal Nodes in Hypopharynx Cancer on Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2007, 25, 599-601.	1.6	11
215	Behavior of oral squamous cell carcinoma in subjects with prior lichen planus. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 136, 401-404.	1.9	24
216	Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1369-1376.	0.8	44

#	ARTICLE	IF	CITATIONS
217	Novel agents for the treatment of mucositis. <i>The Journal of Supportive Oncology</i> , 2007, 5, 33-9.	2.3	10
218	Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 134, 916-922.	1.9	96
219	Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2006, 132, 526.	1.2	81
220	Rate of Pathologic Complete Responses to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 2006, 132, 678.	1.2	26
221	Chemoradiotherapy for Adenoid Cystic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 153-157.	1.3	67
222	Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1036-1044.	0.8	26
223	Integrating novel agents into the curative treatment of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 157-159.	2.4	5
224	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 461-467.	2.4	10
225	Long Term Survival With Adjuvant Carboplatin, Paclitaxel, and Radiation Therapy in Anaplastic Thyroid Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 104.	1.3	13
226	Organ Preservation and Treatment Toxicity With Induction Chemotherapy Followed by Radiation Therapy or Chemoradiation for Advanced Laryngeal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 371-378.	1.3	41
227	Chemoradiation-Induced Cell Loss in Human Submandibular Glands. <i>Laryngoscope</i> , 2005, 115, 958-964.	2.0	30
228	Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. <i>Oral Oncology</i> , 2005, 41, 70-76.	1.5	53
229	Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 6976-6981.	1.6	106
230	The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck. , 2005, , 171-185.		2
231	A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 4680-4687.	7.0	65
232	Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer. <i>Laryngoscope</i> , 2004, 114, 1924-1931.	2.0	51
233	Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: Evolution of the sequential treatment approach. <i>Seminars in Oncology</i> , 2004, 31, 778-785.	2.2	66
234	Positron emission tomography with <sup>18</sup> F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. <i>Head and Neck</i> , 2004, 26, 890-896.	2.0	87

#	ARTICLE	IF	CITATIONS
235	HER2 Expression in Salivary Gland Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 944-946.	7.0	193
236	Erythropoietin to treat anaemia in patients with head and neck cancer. <i>Lancet, The</i> , 2004, 363, 79-80.	13.7	20
237	Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 303-306.	2.3	5
238	Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2003, 30, 84-88.	2.2	19
239	Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. <i>Oral Oncology</i> , 2003, 39, 724-727.	1.5	228
240	Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2003, 97, 412-418.	4.1	90
241	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2003, 97, 1589-1589.	4.1	0
242	Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment. <i>Oncologist</i> , 2003, 8, 35-44.	3.7	52
243	Progress and perspectives in chemoprevention of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 339-355.	2.4	5
244	Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 331-338.	2.4	15
245	Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 226-8.	0.3	11
246	A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 58-60; discussion 61-2.	0.3	0
247	Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. <i>Cancer</i> , 2001, 91, 548-554.	4.1	41